TrialInternational journal of hematology2019

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Koji Nagafuji et al.PubMed ↗Publisher ↗

No numbers read from the abstract.